NDAORALTABLET2 Generics Approved
Approved
Mar 2015
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
JADENU (deferasirox) by Novartis is iron chelating activity [moa]. Approved for iron chelator [epc]. First approved in 2015.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JADENU (deferasirox) is an oral iron chelator approved by the FDA in 2015 for treating chronic iron overload in patients with transfusion-dependent anemias and non-transfusion-dependent thalassemia. It works by binding excess iron in the body and facilitating its excretion through urine and feces. The tablet formulation offers a convenient oral alternative to intravenous chelation therapy.
$9MPart D
Peak8.4 years to LOEJADENU remains in peak lifecycle with moderate Part D spending; the brand team maintains a stable commercial infrastructure ahead of patent expiration in 2034.
Mechanism of Action
Iron Chelating Activity
Pharmacologic Class:
Iron Chelator
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS
Started Oct 2019
11 enrolled
Myelodysplastic Syndromes
Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents
Started Feb 2018
39 enrolled
Myelodysplasia
Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis
Started Jan 2018
44 enrolled
Iron Overload
Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (HH)
Started Jan 2018
45 enrolled
Hereditary Hemochromatosis
Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet
Started Jul 2017
148 enrolled
Transfusion-dependent ThalassemiaNon-transfusion-dependent Thalassemia
Worked on JADENU at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.